In this issue: addressing the issue of snake bites and antivenom, the medicinal...
- Pharma Technology Focus: the absence of antivenom in pharma
- EMA publishes safety warning for Pfizer’s Xeljanz in rheumatoid arthritis
- Risk management, sterile pharmaceutical products and a post-Brexit UK pharma industry
- Amanda Feilding Q&A: “Just six UK patients prescribed medical cannabis”
- AbbVie-Roche’s multiple myeloma trials halted by FDA
FDA approves Jazz Pharma’s sleep disorder drug Sunosi
The US Food and Drug Administration has approved Ireland-based Jazz Pharmaceuticals’ Sunosi drug to treat adults suffering from excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea
Pharma Technology Focus: the absence of antivenom in pharma
In this issue: addressing the issue of snake bites and antivenom, the medicinal potential of illegal drugs, tackling rogue online pharmacies, and much more.
EMA publishes safety warning for Pfizer’s Xeljanz in rheumatoid arthritis
The European Medicines Agency has advised patients and clinicians to not exceed the 5mg twice daily recommendation dose of Pfizer’s Xeljanz (tofacitinib) for rheumatoid arthritis.
FDA advisory committee fails to fully endorse Sanofi’s Dengvaxia
Even if Sanofi receives FDA approval for Dengvaxia, the impact of this licensure will be minimal.
Amanda Feilding Q&A: “Just six UK patients prescribed medical cannabis”
Amanda Feilding has dedicated her life to campaigning to amend global policies towards illegal drugs by conducting scientific research into the medical benefits of cannabis and psychedelics through her NGO, the Beckley Foundation. Allie Nawrat talks to Feilding about the medicinal potential of these compounds and progress towards their legalisation on this basis.
AbbVie-Roche’s multiple myeloma trials halted by FDA
AbbVie has announced the US Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax for multiple myeloma.
Sage’s postpartum depression drug Zulresso gets FDA approval
Sage Therapeutics has secured FDA approval for its Zulresso injection to treat postpartum depression.
FDA approves Roche’s Tecentriq for fourth oncology indication
Swiss pharmaceutical giant Roche has announced the US Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for adults with extensive stage small cell lung cancer (SCLC).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.